search button
Open Access

Dynamics of APRI and FIB‑4 in HCV cirrhotic patients who achieved SVR after DAA therapy

  • Authors:
    • Anca Leuştean
    • Cristina Popescu
    • Luciana Nichita
    • Cătălin Tilişcan
    • Victoria Aramă

  • View Affiliations

  • Published online on: November 26, 2020     https://doi.org/10.3892/etm.2020.9531
  • Article Number: 99

  • Copyright: © Leuştean et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

There are limited data available on the regression of fibrosis in hepatitis C virus (HCV) patients who have achieved sustained virologic response (SVR) after interferon‑free treatments. Moreover, a perfect method for assessing liver fibrosis and its dynamics has not been established yet. The main objective of this study was to evaluate the dynamics of aspartate aminotransferase to platelet ratio index (APRI) and Fibrosis‑4 (FIB‑4) scores in patients with HCV who registered SVR. We performed ROC curve analysis to evaluate the diagnostic performance of APRI and FIB‑4 scores in determining the presence of cirrhosis in comparison to FibroTest. In total 251 patients were enrolled: 164 cirrhotic and 83 non‑cirrhotic patients, and they were evaluated at baseline, at 6 and at 12 months post‑end of treatment (EOT). In the cirrhotic group, at baseline, there was a weak but statistically significant correlation between APRI and FibroTest (τ=0.173, P=0.001), as well as between FIB‑4 and FibroTest (τ=0.265, P<0.001). At the 6-month follow‑up, APRI no longer correlated with FibroTest (τ=0.144, P=0.057), while FIB‑4 was correlated (τ=0.256, P=0.001). The same pattern was shown at 12 months post‑EOT. Between baseline and the 6-month evaluation, there was a significant decrease in APRI (P<0.001) and FIB‑4 (P<0.001) scores, but for the next follow‑up period, there was no reduction. In the non‑cirrhotic group, APRI and FIB‑4 did not correlate with the FibroTest value at any of the evaluation times. There was a significant difference between baseline and the 6-month visit for APRI (P=0.01) and for FIB‑4 (P=0.014). The areas under the receiver operating characteristics curve (AUROCs) for the presence of cirrhosis compared with FibroTest for APRI and FIB‑4 were 0.682 [95% confidence interval (CI), 0.613‑0.752] and 0.693 (95% CI 0.625‑0.76). Both APRI and FIB‑4 prove to be easy, quick and inexpensive tools for screening HCV cirrhosis, with moderate diagnostic accuracy and FIB‑4 can be useful for monitoring patients post‑EOT.
View Figures
View References

Related Articles

Journal Cover

January-2021
Volume 21 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.7
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Leuştean A, Popescu C, Nichita L, Tilişcan C and Aramă V: Dynamics of APRI and FIB‑4 in HCV cirrhotic patients who achieved SVR after DAA therapy. Exp Ther Med 21: 99, 2021
APA
Leuştean, A., Popescu, C., Nichita, L., Tilişcan, C., & Aramă, V. (2021). Dynamics of APRI and FIB‑4 in HCV cirrhotic patients who achieved SVR after DAA therapy. Experimental and Therapeutic Medicine, 21, 99. https://doi.org/10.3892/etm.2020.9531
MLA
Leuştean, A., Popescu, C., Nichita, L., Tilişcan, C., Aramă, V."Dynamics of APRI and FIB‑4 in HCV cirrhotic patients who achieved SVR after DAA therapy". Experimental and Therapeutic Medicine 21.1 (2021): 99.
Chicago
Leuştean, A., Popescu, C., Nichita, L., Tilişcan, C., Aramă, V."Dynamics of APRI and FIB‑4 in HCV cirrhotic patients who achieved SVR after DAA therapy". Experimental and Therapeutic Medicine 21, no. 1 (2021): 99. https://doi.org/10.3892/etm.2020.9531